全文获取类型
收费全文 | 213818篇 |
免费 | 38113篇 |
国内免费 | 7368篇 |
专业分类
耳鼻咽喉 | 6010篇 |
儿科学 | 5974篇 |
妇产科学 | 2843篇 |
基础医学 | 9001篇 |
口腔科学 | 2499篇 |
临床医学 | 34744篇 |
内科学 | 54758篇 |
皮肤病学 | 8295篇 |
神经病学 | 17439篇 |
特种医学 | 9008篇 |
外国民族医学 | 17篇 |
外科学 | 47857篇 |
综合类 | 14367篇 |
现状与发展 | 95篇 |
一般理论 | 3篇 |
预防医学 | 12332篇 |
眼科学 | 4753篇 |
药学 | 8179篇 |
76篇 | |
中国医学 | 4800篇 |
肿瘤学 | 16249篇 |
出版年
2024年 | 1029篇 |
2023年 | 6022篇 |
2022年 | 4423篇 |
2021年 | 7005篇 |
2020年 | 9186篇 |
2019年 | 4459篇 |
2018年 | 9800篇 |
2017年 | 9769篇 |
2016年 | 10488篇 |
2015年 | 11710篇 |
2014年 | 19465篇 |
2013年 | 19745篇 |
2012年 | 10962篇 |
2011年 | 11433篇 |
2010年 | 14692篇 |
2009年 | 17803篇 |
2008年 | 9594篇 |
2007年 | 7627篇 |
2006年 | 9647篇 |
2005年 | 6538篇 |
2004年 | 4837篇 |
2003年 | 3586篇 |
2002年 | 3324篇 |
2001年 | 4795篇 |
2000年 | 3863篇 |
1999年 | 3921篇 |
1998年 | 4001篇 |
1997年 | 3825篇 |
1996年 | 3659篇 |
1995年 | 3473篇 |
1994年 | 2154篇 |
1993年 | 1669篇 |
1992年 | 1504篇 |
1991年 | 1524篇 |
1990年 | 1156篇 |
1989年 | 1267篇 |
1988年 | 1090篇 |
1987年 | 907篇 |
1986年 | 931篇 |
1985年 | 743篇 |
1984年 | 581篇 |
1983年 | 522篇 |
1982年 | 523篇 |
1981年 | 414篇 |
1980年 | 360篇 |
1979年 | 315篇 |
1978年 | 340篇 |
1977年 | 401篇 |
1975年 | 282篇 |
1972年 | 309篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
5.
Elizabeth A. Mosley PhD MPH Amy J. Schulz PhD MPH MSW Lisa H. Harris MD PhD Barbara A. Anderson PhD 《Women & health》2020,60(7):806-820
ABSTRACT Abortion is legal in South Africa, but negative abortion attitudes remain common and are poorly understood. We used nationally representative South African Social Attitudes Survey data to analyze abortion attitudes in the case of fetal anomaly and in the case of poverty from 2007 to 2016 (n = 20,711; ages = 16+). We measured correlations between abortion attitudes and these important predictors: religiosity, attitudes about premarital sex, attitudes about preferential hiring and promotion of women, and attitudes toward family gender roles. Abortion acceptability for poverty increased over time (b = 0.05, p < .001), but not for fetal anomaly (b = ?0.008, p = .284). Highly religious South Africans reported lower abortion acceptability in both cases (Odds Ratio (OR)anomaly = 0.85, p = .015; ORpoverty = 0.84, p = .02). Premarital sex acceptability strongly and positively predicted abortion acceptability (ORanomaly = 2.63, p < .001; ORpoverty = 2.46, p < .001). Attitudes about preferential hiring and promotion of women were not associated with abortion attitudes, but favorable attitudes about working mothers were positively associated with abortion acceptability for fetal anomaly ((ORanomaly = 1.09, p = .01; ORpoverty = 1.02, p = .641)). Results suggest negative abortion attitudes remain common in South Africa and are closely tied to religiosity, traditional ideologies about sexuality, and gender role expectations about motherhood. 相似文献
6.
7.
8.
全国名中医天津中医药大学第一附属医院针灸科武连仲教授用多年的临床经验总结概括出针刺的理、法、方、穴、术,其创立的"通经止痛"针刺疗法在临床中疗效佳,武老在治疗坐骨神经痛时,取足太阳膀胱经和足少阳胆经具有走窜针感的经穴为主穴,其配伍精确,组方严密,手法独特,可供临床参考。本文将武老运用"痛经止痛"针刺法治疗坐骨神经痛的经验从"理、法、方、穴、术"方面做浅述。 相似文献
9.
血管生长因子在血管新生过程中起着重要作用.大量的动物研究显示在给予血管生长因子后能够有效地促进缺血心肌的血管新生,改善局部血流灌注,提高心功能.但由于临床Ⅱ期试验未取得预期的阳性结果,给治疗性血管新生的应用带来了新的挑战,众多问题有待进一步优化和解决. 相似文献
10.